(Q35751679)

10 August 2017

1 reference

title

Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus (English)

1 reference

10 August 2017

1 reference

1

Greg L Plosker

1 reference

10 August 2017

2

David P Figgitt

1 reference

10 August 2017

1 January 2004

1 reference

10 August 2017

1 reference

10 August 2017

22

1 reference

10 August 2017

6

1 reference

10 August 2017

389-411

1 reference

https://scigraph.springernature.com/pub.10.2165/00019053-200422060-00005

10 August 2017

0 references

cites work

Effect of repaglinide addition to metformin monotherapy on glycemic control in patients with type 2 diabetes.

1 reference

12 December 2020

Repaglinide/troglitazone combination therapy: improved glycemic control in type 2 diabetes.

1 reference

12 December 2020

Assessing the impact of complications on the costs of Type II diabetes.

1 reference

12 December 2020

The direct medical cost of type 2 diabetes

1 reference

12 December 2020

The rising global burden of diabetes and its complications: estimates and projections to the year 2010.

1 reference

12 December 2020

U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. U.K. Prospective Diabetes Study Group

1 reference

12 December 2020

Stimulation of insulin release by non-sulfonylurea hypoglycemic agents: the meglitinide family

1 reference

12 December 2020

The effect of type 2 diabetes mellitus on health-related quality of life (HRQOL).

1 reference

12 December 2020

Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up

1 reference

12 December 2020

Clinical pharmacokinetics of nateglinide: a rapidly-absorbed, short-acting insulinotropic agent

1 reference

12 December 2020

Meglitinide analogues in the treatment of type 2 diabetes mellitus

1 reference

12 December 2020

The effect of prandial glucose regulation with repaglinide on treatment satisfaction, wellbeing and health status in patients with pharmacotherapy naïve Type 2 diabetes: a placebo-controlled, multicentre study

1 reference

12 December 2020

Comparison between repaglinide and glipizide in Type 2 diabetes mellitus: a 1-year multicentre study

1 reference

12 December 2020

Postprandial blood glucose as a risk factor for cardiovascular disease in Type II diabetes: the epidemiological evidence.

1 reference

12 December 2020

Therapy focused on lowering postprandial glucose, not fasting glucose, may be superior for lowering HbA1c. IOEZ Study Group.

1 reference

12 December 2020

Epidemiology of diabetes.

1 reference

12 December 2020

Economic model of first-line drug strategies to achieve recommended glycaemic control in newly diagnosed type 2 diabetes mellitus.

1 reference

12 December 2020

A comparison of repaglinide and glibenclamide in the treatment of type 2 diabetic patients previously treated with sulphonylureas.

1 reference

12 December 2020

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

1 reference

12 December 2020

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

1 reference

12 December 2020

Lifetime Costs of Complications Resulting From Type 2 Diabetes in the U.S

1 reference

12 December 2020

Comparison of glycaemic control and cardiovascular risk profile in patients with type 2 diabetes during treatment with either repaglinide or metformin

1 reference

12 December 2020

Nonfasting plasma glucose is a better marker of diabetic control than fasting plasma glucose in type 2 diabetes.

1 reference

12 December 2020

1 reference

12 December 2020

Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study.

1 reference

12 December 2020

Insulin secretagogues

1 reference

12 December 2020

Mealtime glucose regulation with nateglinide in healthy volunteers: comparison with repaglinide and placebo

1 reference

12 December 2020

The clinical practice improvement (CPI) model and how it is used to examine the availability of pharmaceuticals and the utilisation of ambulatory healthcare services in HMOs. Results from the Managed Care Outcomes Project (MCOP)

1 reference

12 December 2020

Efficacy and safety of combination therapy: repaglinide plus metformin versus nateglinide plus metformin.

1 reference

12 December 2020

Stimulation of insulin release by repaglinide and glibenclamide involves both common and distinct processes

1 reference

12 December 2020

Estimates of direct medical costs for microvascular and macrovascular complications resulting from type 2 diabetes mellitus in the United States in 2000.

1 reference

12 December 2020

Mechanism of action of a new class of insulin secretagogues

1 reference

12 December 2020

Clinical pharmacokinetics and pharmacodynamics of repaglinide

1 reference

12 December 2020

Preclinical and clinical studies on safety and tolerability of repaglinide

1 reference

12 December 2020

Repaglinide in type 2 diabetes: a 24-week, fixed-dose efficacy and safety study

1 reference

12 December 2020

The costs of type 2 diabetes mellitus in Italy: a CODE-2 sub-study

1 reference

12 December 2020

Prandial glucose regulation with repaglinide: its clinical and lifestyle impact in a large cohort of patients with Type 2 diabetes

1 reference

12 December 2020

Clinical significance, pathogenesis, and management of postprandial hyperglycemia

1 reference

12 December 2020

Comparison of repaglinide vs. gliclazide in combination with bedtime NPH insulin in patients with Type 2 diabetes inadequately controlled with oral hypoglycaemic agents

1 reference

12 December 2020

Insulinotropic meglitinide analogues

1 reference

12 December 2020

Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics and pharmacodynamics of repaglinide: potentially hazardous interaction between gemfibrozil and repaglinide

1 reference

12 December 2020

Repaglinide: a review of its therapeutic use in type 2 diabetes mellitus

1 reference

12 December 2020

Resource consumption and costs in Dutch patients with Type 2 diabetes mellitus. Results from 29 general practices

1 reference

12 December 2020

A 1-year multicenter randomized double-blind comparison of repaglinide and glyburide for the treatment of type 2 diabetes. Dutch and German Repaglinide Study Group.

1 reference

12 December 2020

The mechanisms underlying the unique pharmacodynamics of nateglinide

1 reference

12 December 2020

Revealing the cost of Type II diabetes in Europe.

1 reference

12 December 2020

A comparison of costs for four oral antidiabetic regimens within a managed care population.

1 reference

12 December 2020

The progressive cost of complications in type 2 diabetes mellitus

1 reference

12 December 2020

Treatment of type 2 diabetes with a combination regimen of repaglinide plus pioglitazone

1 reference

12 December 2020

The projected health care burden of Type 2 diabetes in the UK from 2000 to 2060.

1 reference

12 December 2020

Economic costs of diabetes in the US in 2002.

1 reference

12 December 2020

A randomized placebo-controlled trial of repaglinide in the treatment of type 2 diabetes.

1 reference

12 December 2020

Repaglinide versus glyburide: a one-year comparison trial.

1 reference

12 December 2020

Health and economic effects of adding nateglinide to metformin to achieve dual control of glycosylated hemoglobin and postprandial glucose levels in a model of type 2 diabetes mellitus

1 reference

12 December 2020

Flexible meal-related dosing with repaglinide facilitates glycemic control in therapy-naive type 2 diabetes

1 reference

12 December 2020

High prevalence of undiagnosed diabetes mellitus in Southern Germany: target populations for efficient screening. The KORA survey 2000.

1 reference

12 December 2020

Repaglinide versus metformin in combination with bedtime NPH insulin in patients with type 2 diabetes established on insulin/metformin combination therapy

1 reference

12 December 2020

The impact of type 2 diabetes mellitus on daily functioning.

1 reference

12 December 2020

Age and the burden of death attributable to diabetes in the United States

1 reference

12 December 2020

10.2165/00019053-200422060-00005

Identifiers

DOI

1 reference

PubMed ID

15099124

Dimensions Publication ID

10 August 2017

1048615361

0 references

Fatcat ID

release_h32iq2cuhfcobezcknybyokbci

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/h32iq2cuhfcobezcknybyokbci

24 November 2022

mapped directly with Wikidata item

PubMed ID

15099124

1 reference

PubMed ID

15099124